FUJIAN COSUNTER PHARMACEUTICAL CO., LTD.

Fujian Cosunter Pharmaceutical Co., Ltd.

300436

CNE100001YZ0

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
16.88 ^CNY	-1.34%		+4.00%	-34.14%

Apr. 19	Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
2023	Jiangsu Zhongxing Pharm Co., Ltd. cancelled the transaction announced on July 5, 2021	CI

Fujian Cosunter Pharmaceutical Co., Ltd.(XSEC:300436) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Fujian Cosunter Pharmaceutical Co., Ltd.

Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 19	CI
Jiangsu Zhongxing Pharm Co., Ltd. cancelled the transaction announced on July 5, 2021	Dec. 28	CI
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Fujian Cosunter Pharmaceutical Co., Ltd.(XSEC:300436) added to S&P Global BMI Index	23-09-18	CI
Fujian Cosunter Pharmaceutical Co., Ltd. agreed to acquire remaining 5.8333% stake in Jiangsu Zhongxing Pharm Co., Ltd. from Zhang Zhijun for CNY 10.6 million.	23-09-11	CI
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Cosunter Pharma Signs 14 Million Yuan Equipment Purchase Deal	23-06-27	MT
Fujian Cosunter Pharma's Unit Completes Clinical Trials on COVID-19 Drug	23-06-21	MT
Fujian Cosunter Pharma Gets Nod to Market Men's Drug	23-06-19	MT
Fujian Cosunter Pharma Completes Enrollment for COVID-19 Drug; Shares Drop 3%	23-05-05	MT
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-20	CI
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-20	CI
Fujian Cosunter Pharma Unit Gets Drug Production License from Provincial Regulator	23-03-15	MT
Chinese Shares End Mixed; Cosunter Pharma Rallies 11% as COVID-19 Drug Seen More Effective Versus Pfizer's	23-01-10	MT
Fujian Cosunter Pharma Says COVID-19 Drug More Effective Than Pfizer’s Paxlovid; Shares Rally 14%	23-01-09	MT
Fujian Cosunter Pharma Selling 948 Million Yuan Shares to Fund New Drug Research Platform	23-01-09	MT
Fujian Cosunter Pharmaceutical Co., Ltd. announced that it expects to receive CNY 948 million in funding	23-01-04	CI
Fujian Cosunter Pharma Enrolls First Patient for Anti-COVID Drug Trial	22-12-22	MT
Fujian Cosunter’s Trial of Anti-COVID Tablets Shows Drug’s Safety; Shares Up 4%	22-12-12	MT
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-24	CI
Fujian Cosunter Subsidiary Gets Approval to Test Tablets for COVID-19 Patients	22-09-26	MT
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-07-27	CI
Fujian Cosunter Jintang Pharmaceutical Co., Ltd. announced that it expects to receive CNY 30 million in funding from Fujian Cosunter Pharmaceutical Co., Ltd.	22-07-26	CI
Fujian Cosunter Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-21	CI
Fujian Cosunter Jintang Pharmaceutical Co., Ltd. announced that it expects to receive CNY 40 million in funding from Fujian Cosunter Pharmaceutical Co., Ltd.	22-03-08	CI

Chart Fujian Cosunter Pharmaceutical Co., Ltd.

Duration

Period

Chart Fujian Cosunter Pharmaceutical Co., Ltd.

More charts

Fujian Cosunter Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of nucleoside anti-HBV drugs. The Company's major products include Adefovir Dipivoxil Tablets, Lamivudine Tablets, Entecavir Capsules and other nucleoside anti-HBV drugs. The Company also produces over-the-counter (OTC) drugs, such as ferrous fumarate and ganoderma capsules.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
FUJIAN COSUNTER PHARMACEUTICAL CO., LTD.	-34.14%	371M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals